Research Article

Novel Molecular Markers of Malignancy in Histologically Normal and Benign Breast

Aejaz Nasir,1,2,3,4 Dung-Tsa Chen,5 Mike Gruidl,6 Evita B. Henderson-Jackson,1,7 Chinnambally Venkataramu,6 Susan M. McCarthy,5 Heyoung L. McBride,9 Eleanor Harris,9 Nazanin Khakpour,8 and Timothy J. Yeatman6,8

1 Department of Anatomic Pathology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
2 Department of M2Gen Pathology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
3 Department of Experimental Therapeutics, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
4 Oncology Biomarker Sciences Group, Diagnostic & Experimental Medicine, Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN 46285, USA
5 Department of Biostatistics, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
6 Department of Molecular Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
7 Department of Pathology & Laboratory Medicine, School of Medicine, University of South Florida, Tampa, FL 33620, USA
8 Department of Radiation Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
9 Department of Surgery, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA

Correspondence should be addressed to Aejaz Nasir, nasir_aejaz@lilly.com and Timothy J. Yeatman, tim.yeatman@m2gen.com

Received 24 October 2010; Accepted 17 March 2011

Academic Editor: Nicole Nicosia Esposito

Copyright © 2011 Aejaz Nasir et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

To detect the molecular changes of malignancy in histologically normal breast (HNB) tissues, we recently developed a novel 117-gene-malignancy-signature. Here we report validation of our leading malignancy-risk-genes, topoisomerase-2-alpha (TOP2A), minichromosome-maintenance-protein-2 (MCM2) and “budding-uninhibited-by-benzimidazoles-1-homolog-beta” (BUB1B) at the protein level. Using our 117-gene malignancy-signature, we classified 18 fresh-frozen HNB tissues from 18 adult female breast cancer patients into HNB-tissues with low-grade (HNB-LGMA; N = 9) and high-grade molecular abnormality (HNB-HGMA; N = 9). Archival sections of additional HNB tissues from these patients, and invasive ductal carcinoma (IDC) tissues from six other patients were immunostained for these biomarkers. TOP2A/MCM2 expression was assessed as staining index (%) and BUB1B expression as H-scores (0–300). Increasing TOP2A, MCM2, and BUB1B protein expression from HNB-LGMA to HNB-HGMA tissues to IDCs validated our microarray-based molecular classification of HNB tissues by immunohistochemistry. We also demonstrated an increasing expression of TOP2A protein on an independent test set of HNB/benign/reduction mammoplasties, atypical-ductal-hyperplasia with and without synchronous breast cancer, DCIS and IDC tissues using a custom tissue microarray (TMA). In conclusion, TOP2A, MCM2, and BUB1B proteins are potential molecular biomarkers of malignancy in histologically normal and benign breast tissues. Larger-scale clinical validation studies are needed to further evaluate the clinical utility of these molecular biomarkers.

1. Introduction

Despite recent advances in biomarker discovery, no clinically proven biomarkers of increased breast cancer risk have been identified and validated in histologically normal breast. However, there is increasing evidence in the current literature for the presence of specific genetic abnormalities in histologically normal breast tissue in patients with and without breast cancer [1–10]. Such genetic abnormalities are often common to the tumor and their matched histologically normal breast tissues, suggesting their association with subsequent development of breast cancer in those patients. Whether such
molecular abnormalities are the cause or the effect of the development of breast cancer is largely unknown. Also the degree of expression and microanatomical distribution of these molecular abnormalities in histologically normal/benign breast tissues is still poorly defined.

In order to elucidate the molecular changes of malignancy in HNB tissues, we used the Affymetrix platform to profile a large prospective series of fresh-frozen HNB tissues and invasive ductal breast carcinomas (IDCs). Based on the differential expression of a number of IDC-specific genes in HNB tissues, we developed a novel 117-gene malignancy signature for molecular classification of HNB tissues into two subsets that we designated as those with high-grade and low-grade molecular abnormalities. We subsequently validated our microarray data on HNB tissues using real-time PCR (qPCR) [11] and demonstrated additional utility of our malignancy signature by cross-validation analyses on publically available breast data sets.

Many of the genes in our 117-gene signature were “proliferation genes.” Some of these “proliferation genes” (TOP2A, MCM2, and BUB1B) are also important targets for breast cancer therapy. Here we report cross-platform validation of these 3 genes as our leading candidate malignancy genes at the protein level. We used immunohistochemistry on a new set of archival sections of HNB tissues from 18 breast cancer/DCIS/prophylactic mastectomy patients whose breast tissues (cancer and normal) were used to derive our 117-gene malignancy signature in the original microarray experiment. Since the cells lining the terminal duct lobular units (TDLUs) are thought to be the precursor cells of breast cancer [12], in this cross-platform (microarray to IHC) validation analysis we focused primarily on the immunohistochemical expression of TOP2A, MCM2, and BUB1B in the histologically normal TDLUs, although we believe that these proteins may also be useful in the molecular stratification of benign breast disease and premalignant breast lesions such as atypical ductal hyperplasia (ADH).

2. Materials and Methods

2.1. Patients and Specimens. This study was carried out under approval by the Institutional Review Board (IRB) at the University of South Florida, Tampa, FL. It included 24 adult female patients who underwent mastectomy for their breast cancers at Moffitt Cancer Center (MCC), Tampa, FL between 2002 and 2005. Eighteen of these patients had fresh-frozen histologically normal breast (HNB) tissues previously analyzed using Affymetrix Plus 2.0 Gene chip to develop a 117 gene signature to be used for molecular classification of histologically normal breast tissues. Based on the expression levels of 117-genes in our malignancy signature (Figure 1), these 18 specimens were classified as HNB tissues with high-grade and low-grade molecular abnormalities (HNB-HGMA; N=9 and HNB-LGMA; N=9). Mean ages for patients with HNB-HGMA and HNB-LGMA were 50 and 55 years, respectively. Pertinent clinicopathologic data, based on information available from MCC and Contributing Institutions’ Surgical Pathology reports, electronic patient records, MCC Cancer Registry, and retrospective review of all available H&E slides from MCC Pathology Archives and outside institutions, is summarized in Table 1.

All available formalin fixed, paraffin-embedded (FFPE) sections from the mastectomies of the study patients (N = 18) were reviewed by an experienced breast pathologist (AN) to select HNB tissue blocks for immunohistochemical validation of 3 of our leading malignancy-risk genes (TOP2A, BUB1B, and MCM2). The selection of FFPE block representative of each HNB tissue was based on the presence of maximum number of histologically normal terminal duct lobule units (TDLUs) on a single H&E stained section among all of the archival sections reviewed from that patient. Archival tumor sections from 6 other adult female patients (mean patient age: 69 years) with IDCs (Cases 1–6; Table 1) were selected as positive tissue controls to validate the immunohistochemical expression of TOP2A, MCM2, and BUB1B protein on archival sections of HNB tissues. Table 2 compares ages for the 3 patient groups in this analysis.

2.2. TOP2A, MCM2, and BUB1B Protein Immunohistochemistry. Five-micron thick serial FFPE sections from each selected IDC (N = 6), HNB-HGMA (N = 9), and HNB-LGMA (N = 9) tissue block were stained with H&E, and for TOP2A, MCM2, and BUB1B protein proteins, using immunohistochemical (IHC) protocols optimized in the Tissue Core Laboratory at our institute (AN). The IHC staining was carried out using a Ventana Discovery XT automated system (Ventana Medical Systems, Tucson, AZ, USA) as per manufacturer’s protocol with proprietary reagents. Briefly, slides were deparaffinized on the automated system with EZ Prep solution (Ventana). Enzymatic retrieval was used with Protease 1 solution (Ventana).

The mouse monoclonal antibody that reacts with human TOP2A protein (#MS-1819-SO, Neomarkers) was used at a 1:50 concentration in Dako antibody diluent and incubated for 60 min. The mouse monoclonal antibody that reacts with human MCM2 protein (#MS1746PO, Neomarkers) was used at a 1:100 concentration in Dako antibody diluent and incubated for 4 hours. The BUB1B staining required a 4-minute treatment with Ventana Protease 1 prior to a 60-minute incubation with the BUB1B antibody (diluted 1:100, Abcam, #AB54894). The Ventana Omni Anti-Mouse HRP Secondary Antibody (prediluted) was used for 16 min. The detection system used was the Ventana Omni UltraMap kit, and slides were then counterstained with hematoxylin. Slides were dehydrated and cover-slipped as per standard tissue core laboratory protocol.

2.3. Control Tissues Used for Immunohistochemical Optimization and Test Runs. Positive control tissues that were used for optimization of the above IHC protocols included tonsillar lymphoid tissue for TOP2A and MCM2 and spleen for BUB1B protein, per manufacturer’s recommendations. For negative controls, the respective primary antibodies were replaced by commercially available nonimmunized normal serum. Both types of controls showed satisfactory results.

2.4. Scoring of Immunohistochemical Expression of TOP2A and MCM2 Proteins. The stained slides were evaluated by the
| Case no. | Tissue core ID (frozen specimens for microarray) | Patient age (Years) | Side of breast sampled | Outside institution Date of first-tissue diagnosis of BRCA | Pathologic diagnosis of BRCA | Surgical procedure at first-tissue diagnosis of BRCA | Moffitt Cancer Center (MCC) Date of surgical procedure at MCC | Side of breast sampled | Surgical procedure | Axillary LN dissection; INA = Information not available | Final pathologic diagnosis | Histologic grade (Invasive carcinoma) | Tumor size (cm) | DCIS | Other histopathologic findings (resected specimen) |
|---------|-----------------------------------------------|---------------------|------------------------|-------------------------------------------------|-----------------------------|-----------------------------------------------|---------------------------------------------------------------|------------------------|----------------|-------------------------------------------------|-----------------------------|---------------------------------------------|----------------|-----|-------------------------------------------------|
| 1       | X 41                                          | 2001.04.10          | Left                   | Core biopsy                                      | IDC, DCIS, high grade, comedo type | 2005.08.04 Left Lumpectomy                        | Intramammary lymph nodes IDC                                 | 3                      | 5  | Present                                                                                         | X                                                                 |
| 1       | X 41                                          | 2005.08.04          | Right                  | X X X                                           | Modified radical mastectomy | ND                                            | Papillary CA with a focus of IDC IDC 3 4 Present SID: Invasion, multifocal |
| 2       | X 38                                          | 2005.07.01          | Left                   | Core biopsy                                      | IDC 2005.08.03 Left Modified radical mastectomy | SLN-AX                                           | Total mastectomy IDC 3 2.2 Present |
| 3       | X 68                                          | 2005.07.20          | Right                  | INA IDC 2005.08.09 Right Mastectomy SLN-AX IDC 3 2 Present  | Fibroadenomatoid hyperplasia, florid ductal hyperplasia, sclerosing adenosis, microcalcifications |
| 4       | X 47                                          | 2005.11.28          | Left                   | INA IDC 2006.01.09 Left Mastectomy SLN-AX IDC 3 2 Present  | Fibroadenomatoid hyperplasia, florid ductal hyperplasia, sclerosing adenosis, microcalcifications |
| 5       | X 53                                          | 2006.05.09          | Right                  | Core biopsy                                      | IDC 2006.07.31 Right Mastectomy AX Residual IDC 3 2.8 NS Present |
| 6       | X 71                                          | 2006.04.12          | Left                   | Core biopsy                                      | Ductal & Lobular CA 2006.05.23 Left Modified radical mastectomy SLN-AX IDC w/lumbar features 3 4 Present |
| 7       | 1480   61                                     | 2006.05.09          | Right                  | INA IDC 2006.08.01 Right Mastectomy SLN-AX IDC 3 2.6 Absent |
| 7       | X 61                                          | 2006.05.09          | Left                   | X X X                                           | Mastectomy SLN-AX IDC 3 2.6 Absent |
| 8       | 1481   86                                     | 2006.07.31          | Right                  | Core biopsy IDC 2006.08.29 Right Total mastectomy SLN-AX IDC 3 8.5 Present |
| 9       | 1482   52                                     | 2006.02.22          | Left                   | Core biopsy IDC 2006.03.30 Left Total mastectomy, skin-sparing Total mastectomy SLN-AX IDC 3 1.5 Present |
| 10      | 1483   80                                     | 2005.06.13          | Left                   | Excisional biopsy                                | Mucinous Carcinoma 2005.08.16 Left Not done No residual carcinoma |
| 11      | 1484   42                                     | 2005.07.06          | Left                   | Core biopsy DCIS solid type 2005.08.15 Left Mastectomy SLN-AX Residual DCIS NA 0.4 Present DCIS, multifocal |
| 11      | X 42                                          | 2005.08.15          | Right                  | X X X                                           | Mastectomy SLN-AX Benign breast NA NA Absent X |
| Case no. | Tissue core ID (frozen specimens for microarray) | Patient age (Years) | Side of breast sampled | Date of first-tissue diagnosis of BRCA | Outside institution | Surgical procedure at first-tissue diagnosis of BRCA; INA = Information not available | Pathologic diagnosis of BRCA | Date of surgical procedure at MCC | Side of breast sampled | Surgical procedure | Axillary LN dissection = AX; Sentinel LN dissection, axillary = SLN-AX; Not done = ND | Final pathologic diagnosis | Histologic grade (Invasive carcinoma) | Tumor size (cm) | DCIS | Other histopathologic findings (resected specimen) |
|---------|-------------------------------------------------|--------------------|------------------------|--------------------------------------|-------------------|----------------------------------------------------------------------------------|----------------------------|-----------------------------|-----------------|-----------------|---------------------------------------------------------------------------------|------------------------|------------------------|-------------|--------|-----------------------------------------------|
| 12      | 1485                                            | 52                 | Left                   | 2006.03.31                           | Gore biopsy       | IDC                                                                             | 2006.05.30                  | Left                        | Total mastectomy             | Modified radical prophylactic mastectomy | ND                                               | No residual carcinoma | NA            | NA       | Absent                                      |
| 12      | X                                               | 52                 | Right                  | X                                     | X                  | X                                                                               | 2006.05.30                  | Right                      | Modified radical prophylactic mastectomy | SLN-AX                         | DCIS                        | NA            | 1.2        | Present                                    |
| 13      | 1486                                            | 67                 | Right                  | 2006.05.02                           | Gore biopsy       | DCIS                                                                            | 2006.07.12                  | Right                      | Mastectomy                   | Prophylactic mastectomy       | SLN-AX                | Benign breast | NA        | NA       | Absent                                      |
| 14      | X                                               | 67                 | Left                   | X                                     | X                  | X                                                                               | 2006.07.12                  | Left                       | Mastectomy                   | Prophylactic mastectomy       | SLN-AX                | Benign breast | NA        | NA       | Absent                                      |
| 15      | 1488                                            | 49                 | Left                   | 2005.05.23                           | Excisional biopsy | DCIS                                                                            | 2005.08.02                  | Left                       | Mastectomy                   | Total Mastectomy              | SLN-AX                | Residual DCIS | NA        | X        | Present                                    |
| 16      | 1489                                            | 49                 | Left                   | 2005.05.27                           | Excisional biopsy, subareolar | Adenoid cystic CA | 2005.06.14                  | Left                       | Total Mastectomy              | Prophylactic mastectomy       | SLN-AX                | No residual carcinoma | NA        | NA       | Absent                                      |
| 17      | X                                               | 49                 | Right                  | X                                     | X                  | X                                                                               | 2005.06.14                  | Right                      | Mastectomy                   | Prophylactic mastectomy       | SLN-AX                | Benign breast | NA        | NA       | Absent                                      |
| 18      | 1490                                            | 39                 | Right                  | 2005.04.26                           | Excisional biopsy | DCIS solid type Invasive CA                                                     | 2005.06.29                  | Right                      | Mastectomy                   | Prophylactic mastectomy       | SLN-AX                | DCIS, multifocal | NA        | 2.2      | Present                                    |
| 19      | 1491                                            | 85                 | Left                   | 2005.06.30                           | Excisional biopsy | IDC                                                                             | 2005.07.28                  | Left                       | Mastectomy                   | Prophylactic mastectomy       | SLN-AX                | No residual carcinoma | NA        | NA       | Absent                                      |
| 20      | 1492                                            | 47                 | Left                   | 2005.11.11                           | Needle-loc excisional biopsy | IDC                 | 2006.05.02                  | Left                       | Skin-sparing total mastectomy | IDC focal micropapillary features | NA            | 2.5        | Present                                    |
| 19      | X                                               | 47                 | Right                  | 2006.02.27                           | Needle core biopsy | Fibrocystic changes                                                        | 2006.05.02                  | Right                      | Needle-loc excisional biopsy | IDC focal micropapillary features | SLN-AX                | Adenoma      | NA        | Absent                                      |
| 20      | 1493                                            | 55                 | Right                  | 2006.01.03                           | Cytology: Adenocarcinoma | IDC                 | 2006.02.20                  | Right                      | Mastectomy                   | SLN-AX                         | IDC                        | 3            | 2         | NS         | X            |
| 21      | X                                               | 55                 | Left                   | X                                     | X                  | X                                                                               | 2006.02.20                  | Left                       | Mastectomy                   |          | SLN-AX                         | ALH; No invasive carcinoma | NA        | X        | X        | ALH involving lactiferous duct            |
| 21      | X                                               | 50                 | Left                   | X                                     | X                  | X                                                                               | 2006.05.22                  | Right                      | Bilateral nipple sparing mastectomy | SLN-AX                         | No residual carcinoma | NA        | NA       | Absent                                      |
| 22      | 1495                                            | 18                 | Right                  | NA                                     | NA                 | No clinical evidence of invasive carcinoma                                     | 2006.06.19                  | Right                      | Prophylactic mastectomy*     | SLN-AX                         | Benign breast | NA        | NA       | Absent                                      |
| 22      | X                                               | 18                 | Left                   | X                                     | X                  | X                                                                               | 2006.06.19                  | Left                       | Prophylactic mastectomy*     | SLN-AX                         | Benign breast | NA        | NA       | Absent                                      |
| 23      | 1496                                            | 56                 | Right                  | 2006.04.04                           | Unknown            | DCIS                                                                            | 2006.06.15                  | Right                      | Bilateral mastectomy          | SLN-AX                         | No residual DCIS | NA        | NA       | Absent                                      |
| 23      | X                                               | 56                 | Left                   | X                                     | X                  | X                                                                               | 2006.06.15                  | Left                       | Bilateral mastectomy          | SLN-AX                         | Benign breast | NA        | NA       | Absent                                      |
| 24      | 1497                                            | 48                 | Right                  | 2006.06.27                           | Lumpectomy         | IDC, ILC                                                                       | 2006.07.28                  | Right                      | Modified radical mastectomy  | Prophylactic mastectomy       | SLN-AX                | No residual invasive carcinoma; LCIS involves nipple duct | NA        | NA       | Absent                                      |
| 24      | X                                               | 48                 | Left                   | X                                     | X                  | X                                                                               | 2006.07.28                  | Left                       | Modified radical mastectomy  | Prophylactic mastectomy       | ND                        | Benign breast | NA        | NA       | Absent                                      |

* Strong family history of breast cancer and patient tested positive for BRCA1 gene.
Discovery phase completed
Invasive ductal breast carcinomas [41] Histology normal breast tissues [42]—90 patients

Affymetrix 2-genechip data analysis

Prior validation completed: Selected malignancy risk genes on FFPEs (real-time PCR)

Validation of leading proliferation genes at protein level by IHC (TOP2A, MCM2, and BUB1B)
(Protein study)

IHC confirms MAtyp-HNB & MTyp-HNB tissues identified on microarray

Using archival sections of histologically normal/benign breast tissues from original mastectomy specimens and IDC controls

Future plans: Application of TOP2A, MCM2, BUB1B IHC on independent test sets of breast tissues

*Figure 1: Molecular markers of malignancy in histologically normal breast tissues. Context and evolution of our prospective experimental plan.*

*Figure 2: Serial archival sections representative of an IDC stained for H&E, TOP2A, MCM2 and BUB1B proteins. (a) Primary invasive ductal carcinoma (IDC) of the breast, grade 2, featuring focal tubular differentiation. (b, c, d) Distinct nuclear immunoreactivity for TOP2A marking the presence of cycling cells in about 15% of the infiltrating tumor cells, and for MCM2 marking the "licensed" population in about 1/3rd of the infiltrating tumor cells and diffuse cytoplasmic immunoreactivity (2+) with focal cell membrane accentuation for BUB1B protein (Immunoperoxidase staining (IMPOX staining); original magnifications 200x).

breast pathologist on the study with extensive experience in immunohistochemistry (AN). Immunohistochemical staining for TOP2A and MCM2 was localized to the nuclei of the tumor cells and the normal breast epithelium, while the expression of BUB1B protein was localized to the cytoplasm of the tumor and normal breast epithelial cells. In order to calculate TOP2A and MCM2 nuclear staining indices in IDC tissue sections, up to 2000 tumor cells and in the case of histologically normal breast tissues (HNB-HGMA and HNB-LGMA) tissue sections up to 500 nonneoplastic breast epithelial cells were evaluated by absolute counting of positive (stained) and negative (unstained) cells in each section. TOP2A and MCM2 indices were recorded as percent positive nuclei as previously described [13]. As outlined
Figure 3: Serial archival sections representative of histologically normal breast tissues with high-grade molecular abnormality stained for H&E, TOP2A, MCM2 and BUB1B proteins. (a) Portion of a TDLU from a histologically normal breast tissue with high-grade molecular abnormality (Case 22, specimen 1495). Serial sections showing the same TDLU as in (a) with distinct nuclear immunoreactivity for TOP2A (b) and MCM2 (c) in the epithelial cell nuclei, and diffuse cytoplasmic immunoreactivity (2+) for BUB1B protein (d) in the mammary epithelial cells. (IMPOX staining; original magnifications 400x).

in the scheme published by Gonzalez et al. [14], these evaluations were made in the highest expression areas of the tumor and histologically normal breast tissues (Figures 2(b), 2(c), 3(b), 3(c), 4(b), and 4(c)).

In the IDCs, both TOP2A- and MCM2-positive tumor cells were often more frequent at the peripheral/advancing edge of the tumor mass (Figures 2(b) and 2(c)), while in HNB tissues such cells were more randomly distributed within the epithelial lining of the mammary acini and ducts (Figures 3(b), 3(c), 4(b), and 4(c)). Overall, expression of these markers was observed predominantly in the mammary epithelial cells. In some areas, nuclear staining was also noted in an occasional myoepithelial cell in the outer layers of the benign mammary acini and ducts. Since myoepithelial expression was not a consistent finding in most benign mammary lobules, it was not included in the determination of TOP2A and MCM2 index.

2.5. Scoring Immunohistochemical Expression of BUB1B Protein. Since the intensity of cytoplasmic staining and the percentage of epithelial cells stained for BUB1B protein was variable from case to case and from lobule to lobule within the same case, a comprehensive immunohistochemical scoring method (H-score method) [15] was used for semiquantitative evaluation of BUB1B protein expression in the entire tumor and normal breast tissue sections: BUB1B protein staining intensity in the malignant (IDC) or benign breast epithelial cells was scored 0 when there was no cytoplasmic staining, 1+ for weak, 2+ for intermediate, and 3+ for strong cytoplasmic staining. The products of stained epithelial cells (%) and the respective staining intensity (0, 1+, 2+, 3+) were added to calculate the total BUB1B protein immunohistochemical staining score (H-score) for each IDC tissue and for each histologically normal TDLU in the HNB tissue section evaluated (Figure 5). The total number of TDLUs evaluated for immunohistochemical expression of TOP2A, MCM2, and BUB1B proteins in the HNB-HGMA and the HNB-LGMA tissue sections ranged from 6 (no other FFPE section with greater # of TDLUs was found on review of all archival slides on that case) up to a maximum of 39 TDLUs/section (Figure 5). The average number of TDLUs evaluated per HNB tissue section was 31 (range 6 to 39 TDLUs per section) per HNB-HGMA tissue section analyzed and 24 (range of 17–35 TDLUs per section) per HNB-LGMA tissue section (Table 3). For most precise interpretation of immunoreactive nuclei, the sections were assessed using the 20x objective.

2.6. Differential Expression of TOP2A Protein in Independent Sets of Benign, Premalignant, and Cancerous Breast Tissues. Apart from cross-platform validation of 3 of our leading malignancy genes in archival HNB tissue samples, we further demonstrated the differential expression of TOP2A protein on independent test sets of Histologically normal breast
tissues, including reduction mammoplasty samples, benign breast tissue from patients with and without synchronous breast cancer, and a set of DCIS and invasive breast carcinomas in a custom-designed breast TMA (Figure 10).

2.7. Statistical Analysis. Analysis of variance was used to test the differences among the three sample groups (IDC, HNB-HGMA, and HNB-LGMA tissues) with the Tukey method to adjust for P value for pairwise comparison. This approach was used for analyzing the immunohistochemical expression data both from the FFPE sections and the breast TMA. Spearman correlation analysis was used to test the correlation between immunohistochemical expression of TOP2A, MCM2, and BUB1B proteins in the 3 sample groups.

3. Results

3.1. Patient Characteristics. The 18 histologically normal breast tissues with low-grade (N = 9) and high-grade (N = 9) molecular abnormalities were identified based on the differential expression of our breast malignancy genes from a total of 143 frozen normal breast tissue samples collected from mastectomies in patients with invasive breast carcinoma, DCIS, or prophylactic mastectomies (prior microarray experiment). We then summarized pertinent clinicopathologic characteristics of these patients with HNB tissues with low-grade molecular abnormalities (Cases 7–15) and those with high-grade molecular abnormality (Cases 16–24) (Table 1). Four of the nine patients whose HNB tissues showed low-grade molecular abnormality on microarray had the final pathologic diagnosis of IDC, 4 had only DCIS, and 1 had mucinous carcinoma. Of nine patients whose HNB tissues showed high-grade molecular abnormality on microarray, two patients had the final pathologic diagnosis of IDC, one tubular carcinoma, one adenoid cystic carcinoma, one invasive lobular carcinoma, one papillary intracystic carcinoma, 2 DCIS, and one patient had no histologic evidence of malignancy in the prophylactic mastectomy specimen, despite thorough sampling. The last patient underwent prophylactic bilateral mastectomy because of strong family history of breast cancer and had tested positive for the BRCA1 gene.

Mean age for the patient groups with IDCs, HNB-HGMA, and HNB-LGMA tissues was 63, 50, and 55 years, respectively (Table 2). Based on the analysis of variance (ANOVA), the difference in the distribution of patient ages at the time of diagnosis of their breast cancers (and collection of histologically normal tissues for the current analysis) was not statistically significant (P = .29). Since most patients whose normal breast tissues were found to exhibit HGMA or LGMA on prior microarray analysis [11] were perimenopausal, the differential expression of TOP2A, MCM2, and BUB1B proteins (proliferation gene products) in this
Table 2: Patient age distribution for IDC, molecularly high-risk and low-risk, histologically normal breast tissue groups.

|                      | IDC patients | Patients with histologically normal breast tissues with low-grade molecular abnormality on microarray confirmed by IHC | Patients with histologically normal breast tissues with high-grade molecular abnormality on microarray confirmed by IHC |
|----------------------|--------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Mean age             | 63           | 55                                                                                               | 50                                                                                               |
| Standard deviation   | 14.3         | 15.16                                                                                            | 17.48                                                                                            |
| Total no. of cases   | 6            | 9                                                                                               | 9                                                                                               |

Table 3: Mean TOP2A and MCM2 indices and BUB1B protein expression scores in IDCs and molecularly high-risk and low-risk, histologically normal breast tissues.

| Archival specimen type                                      | Average no. of TDLUs evaluated/specimen (Range) | Mean TOP2A index (%) by IHC | Mean MCM2 index (%) by IHC | Mean BUB1B protein expression score (H-score) by IHC (Range) |
|------------------------------------------------------------|--------------------------------------------------|------------------------------|---------------------------|----------------------------------------------------------------|
| IDCs (N = 6)                                               | Not applicable                                   | 27 (15–35)                  | 47 (30–80)                | 149 (80–200)                                                   |
| Histologically normal breast tissues with high-grade molecular abnormality (N = 9) on microarray | 31 (6–39)                                        | 11 (2–30)                   | 20 (8–35)                 | 68 (33–113)                                                   |
| Histologically normal breast tissues with low-grade molecular abnormality (N = 9) on microarray | 24 (17–35)                                       | 2 (1–3)                     | 4 (1–12)                  | 17 (10–22)                                                   |
| *P* value                                                  | .18                                               | <.005                        | <.05                      | <.005                                                          |

3.2. TOP2A, MCM2, and BUB1B Protein Immunohistochemistry

3.2.1. Localization of Immunohistochemical Staining. TOP2A and MCM2 immunostaining was localized to the nuclei of the tumor cells (Figures 2(b) and 2(c)) and benign mammary epithelium (Figures 3(b) and 3(c)), while BUB1B protein immunostaining was cytoplasmic (Figures 2(d) and 3(d)), as has been demonstrated in a variety of normal human tissues [16]. In addition to cytoplasmic localization, an accentuation of BUB1B immunostaining (Figure 2(d)) was notable in cell membranes in some of the cases. Overall, a large proportion of tumor cells in the IDCs demonstrated a distinct nuclear staining for TOP2A (Figure 2(b)) and MCM2 proteins (Figure 2(c)) and cytoplasmic staining for BUB1B protein (Figure 2(d)). However, the expression of these 3 biomarker proteins was found in smaller proportions of the epithelial cells lining the TDLUs present in the HNB-HGMA (Figures 3(b), 3(c), and 3(d)) and HNB-LGMA (Figures 4(b), 4(c), 4(d)) tissues analyzed.

3.2.2. TOP2A Protein Expression in IDCs and Histologically Normal Breast Tissues with High-Grade and Low-Grade Molecular Abnormality on Microarray. Expression of TOP2A was nuclear both in the IDC cells (Figure 2(b)) and in the acinar and ductal epithelial cells present in the histologically normal breast tissues with high-grade (Figure 3(b)) and low-grade (Figure 4(b)) molecular abnormality. Mean TOP2A nuclear staining index values for IDCs and histologically normal breast tissues with high-grade and low-grade molecular abnormality were 27, 11, and 2, respectively. Compared to HNB tissues with low-grade molecular abnormality, TOP2A expression in HNB tissues with high-grade molecular abnormality was significantly higher, both in terms of absolute (Table 4) and mean (Table 3, Figure 6) TOP2A expression indices, thus validating our TOP2A gene expression data from frozen to archival histologically normal breast tissues at the protein level.

MCM2 protein expression in IDCs and histologically normal breast tissues with high-grade and low-grade molecular abnormality on microarray Expression of MCM2 was nuclear both in the IDC cells (Figure 2(c)) and in the acinar and ductal epithelial cells present in the histologically normal breast tissues with high-grade (Figure 3(c)) and low-grade (Figure 4(c)) molecular abnormality. Mean MCM2 staining indexes for IDCs and histologically normal breast tissues with high-grade and low-grade molecular abnormality on microarray were 47, 20, and 4, respectively, showing higher immunohistochemical expression of MCM2 in the HNB tissues with high-grade molecular abnormalities compared to the HNB tissues with low-grade molecular abnormality (Table 4, Figure 7), thus validating the same trend as was evident in our gene expression data. While the majority of cases in HNB tissues with low-grade molecular abnormality had MCM2 index of 1-2%, 2 of the cases (Case #s 9 and 14) (Table 4) had higher MCM2 indices (12% and 8%, resp.), closer to the MCM2 index of some of the HNB tissues with high-grade molecular abnormality, suggesting that there may be a degree of heterogeneity in the expression of MCM2 protein in HNB tissues.

3.2.3. BUB1B Protein Expression in IDCs and Histologically Normal Breast Tissues with High-Grade and Low-Grade Molecular Abnormality on Microarray. Mean BUB1B protein...
cytoplasmic staining scores for IDCs and histologically normal breast tissues with high-grade and low-grade molecular abnormality on microarray were 149, 68, and 17, respectively (Table 3). As compared to low-risk normal breast tissues, abnormality on microarray were 149, 68, and 17, respectively. A BUB1B IHC score is represented by ∆. Both mean and median expression scores for the HNB tissues with high-grade molecular abnormality on microarray (cases 1489–1497) are higher than those for the molecularly low-risk HNB tissues with low-grade abnormality on microarray (cases 1480–1488). Overall, there is a greater variation in the expression scores for the HNB tissues with high-grade molecular abnormality as compared to those with low-grade molecular abnormality (SD = 48.4 versus 24.8; P = .003). The top row reflects the number of TDLUs that were evaluated for IHC expression of BUB1B protein in the respective stained section, representing each histologically normal breast tissue specimen.

3.2.4. Differential Expression of TOP2A, MCM2, and BUB1B Proteins in IDCs and Molecularly High-Risk and Low-Risk, Histologically Normal Breast Tissues. The immunohistochemical expression scores for TOP2A, MCM2, and BUB1B protein in the HNB-HGMA tissues were in the intermediate range between the higher scores (expression) for the IDCs and the lower scores (expression) for the HNB-LGMA tissues (Tables 3 and 4). In fact, for all 3 marker proteins, we observed a trend toward increasing immunohistochemical expression (TOP2A and MCM2 indices and BUB1B protein H-scores) from HNB-LGMA to HNB-HGMA tissues to the IDC tissues analyzed (Figures 6, 7, and 8). Analysis of variance showed that the differences in the immunohistochemical expression scores for TOP2A, MCM2, and BUB1B protein for the three types of tissues were statistically significant (P < .005 for TOP2A and BUB1B protein, and P < .05 for MCM2 for each pairwise comparison using the Tukey method). The differences in expression of these markers for individual pairs (and respective P values) are shown in Figures 6, 7, and 8. Furthermore, in comparing the HNB tissues with low-grade and high-grade molecular abnormality on microarray, the immunohistochemical expression of these 3 marker proteins was highly correlated (Spearman correlation ranges 0.84–0.90 with P value < .0001: r = 0.84 for TOP2A versus BUB1B, r = 0.9 for TOP2A versus MCM2, and r = 0.88 for BUB1B versus MCM2). Taken together, these results validate our microarray expression data for TOP2A, MCM2, and BUB1B at the protein level in archival histologically normal breast tissues.

3.2.5. Pathologic Characteristics of the Cases on Breast TMA Stained for TOP2A. In order to further validate the differential expression of TOP2A protein in various benign, atypical, premalignant, and cancerous breast tissues, we immunostained a breast TMA for TOP2A, using the same IHC protocol as outlined above. The various groups of breast lesions represented on this TMA were as follows.

Benign Lesions (N = 15). In this group seven adult females had undergone unilateral or bilateral reduction mammoplasty (RM). Others underwent diagnostic breast tissue sampling. Final pathologic evaluation showed histologically normal breast tissues with areas of benign breast disease (BBD) (N = 10), BBD with focal ductal hyperplasia (FDH) (N = 2), intraductal papilloma (N = 1), BBD with focus of atypical lobular hyperplasia (ALH) (N = 1), and BBD with focal fibroadenomatoid hyperplasia (N = 1).

Atypical Ductal Hyperplasia (ADH) without Invasive Breast Carcinoma (N = 9). All specimens in this group showed BBD with foci of ADH. In addition, six (66%) cases showed columnar cell change and four (44%) had atypical lobular hyperplasia. There was one case with pseudoangiomatous stromal hyperplasia (PASH) and one case with an intraductal papilloma.

ADH with Ipsilateral Invasive or In Situ Breast Carcinoma (N = 8). All of these cases showed ADH. In addition, three cases showed areas of invasive ductal carcinoma (IDC) while 5 cases had ductal carcinoma in situ (DCIS), 2 cases showed focal columnar cell change, and one of them also had an intraductal papilloma with atypia, a radial scar, and a fibroadenoma.

Figure 5: Whisker plot showing BUB1B protein expression scores for each individual histologically normal breast tissue with high-grade (N = 9) and low-grade molecular abnormality (N = 9) analyzed. The median BUB1B IHC score for each specimen is represented by horizontal lines and symbol +, while mean BUB1B IHC score is represented by Δ. Both mean and median expression scores for the HNB tissues with high-grade molecular abnormality on microarray (cases 1489–1497) are higher than those for the molecularly low-risk HNB tissues with low-grade abnormality on microarray (cases 1480–1488). Overall, there is a greater variation in the expression scores for the HNB tissues with high-grade molecular abnormality as compared to those with low-grade molecular abnormality (SD = 48.4 versus 24.8; P = .003). The top row reflects the number of TDLUs that were evaluated for IHC expression of BUB1B protein in the respective stained section, representing each histologically normal breast tissue specimen.
Figure 6: Immunohistochemical expression of TOP2A protein in HNB tissues with low-grade and high-grade molecular abnormalities and in IDCs. There is an obvious trend toward increasing expression from HNB tissues with low-grade molecular abnormality (white bars) to those with high-grade molecular abnormality (gray bars), and the IDCs (black bars), thus providing evidence for cross-platform validation of our original expression profiling data for TOP2A at the protein level. (a) Is the specimen-wise distribution of immunohistochemical expression of TOP2A for the HNB tissues with low-grade and high-grade molecular abnormality and IDC groups. (b) Is the pairwise comparison of TOP2A immunostaining among the three groups. For each comparison (e.g., IDC versus normal), a mean difference with a 95% confidence interval (95% CI) is displayed to examine whether the difference is statistically significant (A 95% CI deviated away from 0 is statistically significant). The adjusted P value for each comparison, based on Tukey method, is shown.

Ductal Carcinoma In Situ (DCIS) (N = 15). Of the fifteen specimens in this group, 14 (93%) were intermediate to high-nuclear grade DCIS and one low-nuclear grade DCIS. Among these two specimens had areas of adenosis, focal ductal hyperplasia, PASH, and a fibroadenoma in addition.

Invasive Ductal Breast Carcinomas (N = 20). These were histologically confirmed IDCs, of which 2 cases also had focal DCIS, intermediate to high nuclear grade. One IDC showed focal mucinous differentiation.

3.2.6. Differential Expression of TOP2A Protein in Benign, Atypical, and Premalignant, and Cancerous Breast Tissues. We found a striking trend toward increasing expression of TOP2A protein in this independent test set of histologically normal and benign breast tissues, ADH with or without synchronous invasive breast carcinoma, DCIS and invasive ductal breast carcinoma tissues, represented on the breast TMA. These results provide further validation of increasing expression of TOP2A protein along the histologic continuum of various breast lesions from benign to premalignant to invasive breast carcinomas it’s (Figures 9(a), 9(b), 9(c), and 9(d)). For these specimen types, TOP2A protein expression data are summarized in Figure 10.

4. Discussion

There is increasing evidence to support the hypothesis that histologically normal breast tissues contain genetic and epigenetic abnormalities that render them more susceptible to neoplastic transformation and that they might be detected through molecular analyses. In patients with sporadic breast cancer, abnormalities of breast cancer susceptibility genes, including TP53, BRCA1, and BRCA2, have been identified in tumor tissue, and also in histologically normal TDLUs adjacent to carcinoma [17]. In a recent study, Larson et al. found a threefold increase in allelic imbalance (AI) in histologically normal breast tissue from sporadic breast cancer patients and BRCA1 gene mutation carriers as compared to women who underwent reduction mammoplasty [5], suggesting that these genetic abnormalities may be contributing to the risk of development of malignancy. More recently, altered telomeres and unbalanced allelic loci (markers of genetic instability) were found both in human breast cancers and in surrounding histologically normal breast tissues [7]. These findings provide further support to the “cancer field effect” concept recognizing the presence of genetically aberrant cells that may represent high risk cell populations within the histologically normal breast tissues. In a more recent study, [10] elucidated the molecular differences between histologically
Table 4: TOP2A, MCM2, and BUB1B protein expression scores in IDCs, molecularly low-risk and molecularly high risk, histologically normal breast tissues.

| Case no. | Breast tissue specimen category (based on gene expression profiling) | Histologic tumor type on initial biopsy/lumpectomy | Final pathologic diagnosis on mastectomy | Histopathologic findings on archival tissue sections selected for IHC validation | Topoisomerase II-alpha (TOP2A) index (%) | MCM2-index (%) | BUB1B protein expression score (H-score) |
|----------|-------------------------------------------------------------|-------------------------------------------------|----------------------------------------|--------------------------------------------------------------------------|----------------------------------------|----------------|----------------------------------------|
| 1        | Carcinoma                                                  | IDC                                             | IDC, DCIS                              | Invasive Cancer                                                          | 25                                    | 30             | 170                                    |
| 2        | Carcinoma                                                  | IDC                                             | Invasive papillary CA with a focus of IDC | Invasive Cancer                                                          | 30                                    | 30             | 135                                    |
| 3        | Carcinoma                                                  | IDC                                             | IDC                                    | Invasive cancer                                                          | 15                                    | 80             | 145                                    |
| 4        | Carcinoma                                                  | IDC                                             | IDC                                    | Invasive Cancer                                                          | 35                                    | 60             | 80                                     |
| 5        | Carcinoma                                                  | IDC                                             | IDC                                    | Invasive Cancer                                                          | 25                                    | 50             | 165                                    |
| 6        | Carcinoma                                                  | IDC, ILC                                        | IDC w/ lobular features                | Invasive cancer                                                          | 30                                    | 30             | 200                                    |

HNB tissues with low-grade molecular abnormality (HNB-LGMA)

| Case no. | Breast tissue specimen category (based on gene expression profiling) | Histologic tumor type on initial biopsy/lumpectomy | Final pathologic diagnosis on mastectomy | Histopathologic findings on archival tissue sections selected for IHC validation | Topoisomerase II-alpha (TOP2A) index (%) | MCM2-index (%) | BUB1B protein expression score (H-score) |
|----------|-------------------------------------------------------------|-------------------------------------------------|----------------------------------------|--------------------------------------------------------------------------|----------------------------------------|----------------|----------------------------------------|
| 7        | HNB-LGMA 1                                                 | IDC                                             | IDC                                    | Benign breast tissue                                                     | 2.5                                    | 2              | 21                                     |
| 8        | HNB-LGMA 2                                                 | IDC                                             | IDC                                    | Benign breast tissue                                                     | 2.5                                    | 6              | 20                                     |
| 9        | HNB-LGMA 3                                                 | IDC                                             | IDC                                    | Benign breast tissue                                                     | 2.5                                    | 12             | 22                                     |
| 10       | HNB-LGMA 4                                                 | Mucinous carcinoma                              | No residual mucinous carcinoma         | Benign breast tissue                                                     | 1                                      | 2              | 15                                     |
| 11       | HNB-LGMA 5                                                 | DCIS                                            | Residual DCIS, multifocal              | Benign breast tissue                                                     | 1                                      | 1              | 10                                     |
| 12       | HNB-LGMA 6                                                 | IDC                                             | No residual IDC                        | Benign breast tissue                                                     | 1                                      | 1              | 18                                     |
| 13       | HNB-LGMA 7                                                 | DCIS                                            | Residual DCIS                         | Benign breast tissue                                                     | 2                                      | 2              | 15                                     |
| 14       | HNB-LGMA 8                                                 | DCIS                                            | No residual DCIS                       | Benign breast tissue                                                     | 3                                      | 8              | 11                                     |
| 15       | HNB-LGMA 9                                                 | DCIS                                            | Residual DCIS                         | Benign breast tissue                                                     | 1                                      | 1              | 17                                     |

HNB tissues with high-grade molecular abnormality (HNB-HGMA)

| Case no. | Breast tissue specimen category (based on gene expression profiling) | Histologic tumor type on initial biopsy/lumpectomy | Final pathologic diagnosis on mastectomy | Histopathologic findings on archival tissue sections selected for IHC validation | Topoisomerase II-alpha (TOP2A) index (%) | MCM2-index (%) | BUB1B protein expression score (H-score) |
|----------|-------------------------------------------------------------|-------------------------------------------------|----------------------------------------|--------------------------------------------------------------------------|----------------------------------------|----------------|----------------------------------------|
| 16       | HNB-HGMA 1                                                 | Adenoid cystic carcinoma                        | No residual adenoid cystic carcinoma  | Benign breast tissue                                                     | 8                                      | 12             | 33                                     |
| 17       | HNB-HGMA 2                                                 | DCIS                                            | DCIS, multifocal                       | Benign breast tissue                                                     | 12.5                                   | 20             | 64                                     |
| 18       | HNB-HGMA 3                                                 | Intracystic carcinoma                           | No residual intracystic carcinoma     | Benign breast tissue                                                     | 12.5                                   | 8              | 35                                     |
| 19       | HNB-HGMA 4                                                 | IDC                                             | IDC focal papillary features           | Benign breast tissue                                                     | 9                                      | 30             | 113                                    |
| 20       | HNB-HGMA 5                                                 | IDC                                             | IDC                                    | Benign breast tissue                                                     | 2                                      | 12             | 46                                     |
| 21       | HNB-HGMA 6                                                 | IDC                                             | No residual IDC                        | Benign breast tissue                                                     | 15                                     | 30             | 46                                     |
| 22       | HNB-HGMA 7                                                 | No prior biopsy performed                       | Benign breast tissue-patient BRCA1+, strong family history of BC | Benign breast tissue                                                     | 10                                     | 25             | 106                                    |
normal breast tissue from breast cancer patients and reduction mammoplasty controls and found a number of global gene expression abnormalities in the HNB tissues [10].

Using specific epigenetic biomarkers, we have previously mapped a number of DNA methylation changes in histologically normal breast tissues as a potential explanation as to why histologically normal breast tissues are at risk for local recurrence after surgical therapy for breast cancer [6]. We recently developed a 117-gene signature by comparing the gene expression profiles of a large prospective cohort of frozen invasive ductal breast carcinoma (IDC) and histologically normal breast tissues (HNB) from breast cancer patients [11]. This signature was first cross-validated on HNB tissues using qPCR including external validation on previously published datasets [11]. We then used our 117-gene malignancy signature to classify eighteen histologically normal breast tissues with high-grade and low-grade molecular abnormality, based on the level of expression of our top malignancy genes. The leading candidate genes in our malignancy-risk signature were proliferation genes, including TOP2A, MCM2, and BUB1B.

Here we present the results of cross-platform immunohistochemical validation of these candidate malignancy gene products (TOP2A, MCM2, and BUB1B proteins) on archival histological normal breast tissue sections from the mastectomy specimens of the two patient groups in the original microarray experiment (those with HNB tissues with high-grade and low-grade molecular abnormalities). These candidate biomarkers were selected for validation based on the gene expression data and the availability of commercially available antibodies and to further investigate their usefulness as biomarkers of molecular abnormalities in histologically normal and benign breast tissues. We further confirmed the increasing expression of one of our malignancy-risk gene products in the present analysis on independent test sets of histologically normal breast tissues including reduction mammoplasty samples, which mostly represent the specimens with lowest risk of breast malignancy, histologically normal/benign breast tissues from patients with and without synchronous breast cancer and a set of DCIS and invasive breast carcinomas (IDCs) using a custom-designed breast TMA (Figure 10).

One of our leading malignancy risk genes identified on microarray analysis of the histologically normal breast tissues was topoisomerase II alpha (TOP2A). TOP2A is a key enzyme in regulating various chromosomal events during tumor cell replication. It is one of the markers of cell proliferation in human breast cancer [18]. It is also the molecular target for topo II-inhibitors, including anthracyclines (doxorubicin, epirubicin, daunorubicin, idarubicin), epipodophyllotoxins (etoposide, teniposide), actinomycin, mitoxantrone, and others [19–21]. The TOP2A gene is located adjacent to the HER-2 oncogene at the chromosome location 17q12q21 and is either amplified or deleted in breast cancer, with or without HER-2 amplification. Recent evidence suggests that amplification or deletion of TOP2A gene may account for sensitivity or resistance to topo II-inhibitor (anthracycline) therapy in breast cancer [21]. However, little is known about the role of TOP2A in histologically normal/benign breast tissues.

We identified TOP2A as a part of the malignancy-risk signature on our microarray experiment and, in this study, validated its expression at protein level as a potential biomarker of risk of malignancy in histologically normal breast tissues. In the archival sections from histologically normal breast tissues with high-grade and low-grade molecular abnormalities, we evaluated a large number of “morphologically normal TDLUs” and found that the level of expression of TOP2A protein in HNB tissues with high-grade molecular abnormality on microarray was intermediate between the expression levels in the HNB tissues with low-grade molecular abnormality on microarray and invasive ductal breast carcinoma tissues analyzed. Furthermore, the differences in the TOP2A expression levels between the two subsets of molecularly abnormal histologically normal breast tissues and IDCs were statistically significant. Since amplification of TOP2A gene leads to the overexpression of the TOP2A protein and better response to anthracycline therapy [22], while deletion of TOP2A gene leads to marked reduction in the expression of TOP2A protein and primary chemoresistance to TOP2 inhibitor drugs [23], our findings in histologically normal breast tissues, if clinically validated in larger series of histologically normal and benign breast tissues, may have potential implications for future chemopreventive trials in patients with various atypical and pre-malignant breast lesions.

Since TOP2A amplified tumor cells tend to be sensitive to topo-II inhibitor therapy while TOP2A deleted tumor cells tend to be resistant to anthracycline chemotherapy [21], the overall response of a given breast cancer case will depend on
the relative proportions of the 2 cell types. Furthermore, in locally advanced breast cancer, TOP2A levels in the primary tumor have been associated with greater tumor response to anthracycline therapy. It is, therefore, conceivable that in the case of molecularly abnormal histologically normal breast tissues increased expression of TOP2A may not only serve as a molecular biomarker of malignancy, but may also be potentially predictive of chemosensitivity to TOP2A inhibitors, in order to repress proliferation and subsequent transformation. These aspects merit further investigation on larger series of histologically normal and benign breast tissues.

MCM family of proteins are a novel class of proliferation markers, of which MCM2 is part of the prereplicative complex (pre-RC) that is assembled at the site of future DNA replication during the G1 phase to allow genome replication in the subsequent S phase. High-MCM2 index has been shown to correlate with high Ki-67 labeling [24] and has been shown to be a prognostic marker in a variety of human malignancies, including cancers of the esophagus, prostate, stomach and in diffuse large B-cell lymphoma [24–28]. In breast cancers, it appears to be a strong independent prognostic marker and the degree of MCM2 immunoreactivity has been correlated with high histologic grade [14, 29, 30]. In normal breast epithelium MCM2 has been shown to be a more sensitive marker of proliferation than the widely used proliferation marker, Ki-67 [14, 31], since it stains both the cycling cells and also the noncycling cells with proliferative potential [32]. However, not much is known regarding the association between MCM2 expression in normal and benign breast tissues.

In our malignancy-gene signature, MCM2 was one of the leading malignancy-associated genes in a set of histologically normal breast tissues from peri-menopausal breast cancer patients. In this study, using the standard immunohistochemical approach, we have observed that the MCM2 index in HNB tissues with high-grade molecular abnormality was in the intermediate range between IDCs and HNB tissues with low-grade molecular abnormality, thus validating the overexpression of MCM2 protein in the set of HNB tissues that were showed high-grade molecular abnormality on our original microarray data analysis.

In this study, we found expression of MCM2 protein in all of our cases of histologically normal breast tissues. Considering all of our normal breast samples together, the observed MCM2 index ranged from 1% to 35%. This wider variation is a reflection of an inherent case selection bias in our study, since we selected the 2 subsets of histologically normal breast tissues (with high- and low-grade molecular abnormality) based on differential expression of our malignancy- (proliferation-) associated genes. In a set of normal breast tissues from reduction mammoplasties,
Figure 8: Immunohistochemical expression of MCM2 protein in HNB tissues with low-grade and high-grade molecular abnormalities and in IDCs. There is an obvious trend toward increasing expression from HNB tissues with low-grade molecular abnormality (white bars) to those with high-grade molecular abnormality (gray bars), and the IDCs (black bars), thus providing evidence for cross-platform validation of our original expression profiling data for MCM2 at the protein level. (a) Is the specimen-wise distribution of immunohistochemical expression of MCM2 for the HNB tissues with low-grade and high-grade molecular abnormality and IDC groups. (b) Is the pairwise comparison of MCM2 immunostaining among the three groups. The adjusted P value for each comparison, based on Tukey method, is shown on (b).

Shetty et al. found a median MCM2 expression of 35% [31]. This high level of expression is comparable to the highest levels of MCM2 expression in the HNB tissues with high-grade molecular abnormality in our study. Although normal breast tissues in the above study [31] were from the lowest risk specimens (reduction mammoplasties), a probable explanation for higher MCM2 indices in their study was premenopausal status of their patients, since estrogens are known to be a major promoter of proliferation in normal breast epithelium [33]. On the contrary, in our study it is unlikely that the higher MCM2 and other proliferation biomarkers (TOP2A and BUB1B) in the molecularly abnormal breast tissue samples were due to hormonal (estrogen) milieu of the patients studied, since both sets of HNB tissues (with high- and low-grade molecular abnormalities) in our study were from perimenopausal patients without any significant statistical difference in their ages. Therefore, a higher MCM2 expression in histologically normal breast tissues in our study is most likely a true molecular biomarker of malignancy rather than an estrogen-driven phenomenon.

In another recent study of benign breast tissues from 30 patients who underwent lumpectomy for fibrocystic changes, ductal hyperplasia, and fibroadenomas, the overall MCM2 labeling index was from 0% to 12% [30]. This pattern of expression is comparable to the HNB tissues with low-grade molecular abnormality in our study. In our preliminary analysis, we did not find an obvious and linear relationship between the expression of MCM2 and the histologically defined risk categories of benign breast disease. Interestingly, we found higher expression of MCM2 and other proliferation marker proteins in histologically normal TDLUs as compared to the adjacent hyperplastic lobular units and incidental areas of epithelial hyperplasia on the same histologic sections of HNB tissues. This suggests that the expression of our malignancy-associated proliferation marker proteins may be independent of the various histologic risk categories of benign breast disease as was originally defined on the basis of degree of epithelial proliferation and cytologic atypia [34–36], and subsequently endorsed at a Consensus Conference of the College of American Pathologists [37]. We are intrigued by this finding and would like to extend this into a systematic analysis of the expression of these biomarkers and various benign and preneoplastic histologic correlates of breast cancer risk, as they have been recognized in the literature over the years [35, 38–42].

BUB1B protein is a mitotic checkpoint kinase required for cell mitotic divisions following severe cell damage or mutation [43, 44]. It has been associated with cell proliferation both in neoplastic and nonneoplastic tissues [16, 45, 46] and also with tumor progression [47, 48]. BUB1B is also a cellular target of synuclein-gamma (SNCG, also
Figure 9: Immunohistochemical expression of TOP2A protein. (a) Histologically normal breast tissue from a reduction mammoplasty (RM) case featuring lack of nuclear expression of TOP2A in the epithelial cells lining a normal TDLU. (b) Histologically normal breast tissue from a patient with synchronous breast cancer showing positive nuclear staining in 4-5% of the mammary epithelial cells—higher TOP2A expression than the HNB tissues from a reduction mammoplasty case illustrated in (a). (c-d) A larger proportion of epithelial cells are immunoreactive for nuclear TOP2A protein in ductal carcinoma in situ (DCIS) and in the invasive ductal carcinoma (IDC) infiltrating the mammary fat. These cases illustrate an obvious increase in TOP2A protein expression from the lowest risk specimen from a reduction mammoplasty case (a), to the higher-risk specimens (c) and (d) (IMPOX staining for TOP2A; original magnifications 200x).

Figure 10: Mean TOP2A index in independent test sets of histologically normal breast (including reduction mammoplasty tissues), histologically normal and benign breast tissues from patients without and with synchronous cancer, DCIS and invasive breast carcinoma tissues. There is an obvious trend toward increasing TOP2A expression from benign to malignant breast tissues.
known as breast cancer specific gene 1), with which it may interact to inactivate the mitotic checkpoint, and contribute to resistance of breast cancer cells to microtubule inhibitors. Recently, a strong association has been found between BUB1B and other mitotic checkpoint genes and breast cancer risk [49]. Furthermore, checkpoint genes, including BUB1B, are expressed at high levels in breast cancer, both at transcriptional (RNA) and translational (protein) levels [50].

In this study, we have validated overexpression of BUB1B protein in histologically normal breast tissues that were found to be molecularly abnormal on microarray, thus validating our prior microarray and real-time PCR results. Our study suggests that BUB1B overexpression may be a new immunohistochemical biomarker of malignancy in histologically normal breast tissues. It will also be interesting to investigate the role of BUB1B overexpression as a potential therapeutic target for microtubule inhibitors and an immunohistochemical biomarker of predictive of chemosensitivity of atypical and pre-malignant breast lesions to these antimitotic agents.

Expression of hormone receptors is an established predictor of response of breast cancer to hormonal therapy in breast cancer, but markers predictive of chemosensitivity of breast cancer are less well defined [51]. In addition, markers that could predict effective prevention of human breast cancer in high-risk patient populations are largely unknown. Among the proliferation-associated proteins (TOP2A, MCM2, and BUB1B) that we have studied immunohistochemically on a set of IDCs and validated as immunohistochemical biomarkers of malignancy in histologically normal breast tissues, TOP2A and BUB1B protein are also known targets of established chemotherapeutic approaches in breast cancer: anthracyclines and antimicrotubule therapies, respectively. It will, therefore, also be interesting to explore how these biomarkers can be utilized as predictors of breast cancer response to TOP2A and antimicrotubule inhibitors.

5. Summary

To our knowledge, this is the first IHC-based analysis focusing on the pattern of coexpression of newer proliferation-associated proteins (TOP2A, MCM2, and BUB1B) in histologically normal breast tissues. In continuation of our prior transcriptional validation using qPCR, in this immunohistochemical validation study, we have demonstrated significantly higher expression of TOP2A, MCM2, and BUB1B proteins in a set of histologically normal breast tissues that were found to have high-grade molecular abnormality on microarray, based on our novel 117-gene malignancy signature. Taken together, these data further validate our leading candidate malignancy-risk genes (TOP2A, MCM2, and BUB1B) at the protein level. In addition, we have shown incremental expression of TOP2A protein on independent test sets of histologically normal breast tissues (including reduction mammoplasty samples), histologically normal/benign breast tissue from patients with and without synchronous breast cancer, and a set of DCIS and invasive breast carcinomas using a custom breast TMA. This study reveals new information about the coexpression of TOP2A, MCM2, and BUB1B proteins in histologically normal breast tissues and provide preliminary evidence to support further analyses of these proteins on larger series of histologically normal, benign, pre-malignant, and malignant breast tissues. Specifically, determination of TOP2A, MCM2, and BUB1B protein expression status may provide an objective tool to evaluate of the molecular signature of malignancy in histologically normal and benign breast tissues.

The immunohistochemical approach used here offered some distinct technical advantages over other techniques like qPCR or microarray: (1) combined assessment of the degree of expression (high versus low), microanatomical distribution (diffuse versus patchy), tissue (epithelial versus stromal), and subcellular (nuclear versus cytoplasmic) localization of the biomarker proteins in a given sample; (2) comparative evaluation of the relative expression of these marker proteins in histologically normal TDLS and various incidental benign and pre-malignant breast lesions present in the same archival breast tissue sections. We do recognize one of the limitations of our study—the fewer numbers of histologically normal breast tissue analyzed. However, since we have successfully validated the expression of TOP2A, MCM2, and BUB1B proteins in HNB tissues with various grades of molecular abnormalities, we are in the process of now expanding our investigation to larger sample size and a wider range of benign pre-malignant and malignant breast tissues.

6. Conclusions

The data presented in this technical validation study of a novel set of molecular biomarkers (TOP2A, MCM2, and BUB1B proteins) in histologically normal breast tissues confirms our microarray data at the protein level. We have also unraveled a preliminary association between the expression of these marker proteins and different stages of mammary carcinogenesis (histologically normal to benign to pre-malignant and fully invasive malignant breast tissues). Additional studies on larger selection of histologically normal, benign, and pre-malignant breast tissues are needed to fully explore the clinical utility of these biomarkers in the stratification of histologically normal breast and benign and premalignant breast lesions into those with various levels of molecular abnormalities. Such classification may potentially be predictive of response of various benign, atypical, and pre-malignant to targeted chemopreventive approaches.

Abbreviations

TOP2A: Topoisomerase 2 alpha
MCM2: Minichromosome maintenance protein 2
BUB1B: Benzimidazoles 1 homolog beta’
HNB: Histologically normal breast
TDLUs: Terminal duct lobular units
BB: Benign breast
HELUs: Hyperplastic enlarged lobular units
EH: Epithelial hyperplasia
Grant Support

National Cancer Institute RO1 grant, CA098522 “Screening for Breast Cancer Using Molecular Signatures” (PI: TJY).

Future Directions

In the future, the authors would like to evaluate the expression of TOP2A, MCM2, and BUB1B on larger clinical validation sample sets of breast tissues, in order to correlate the immunohistochemical expression of these biomarkers with future risk of development of malignancy and subsequent recurrence.

Conflict of Interests

The authors have no conflict of interests to disclose.

Acknowledgments

The authors would like to thank Mary Willis, Jean Stern, and Debbie Bir in organization of the study material, Tissue Core Histology Laboratory for optimization experiments and services on new antibodies, and Magaly Mendez and Dane Gregor in the preparation of the paper.

References

[1] G. Deng, Y. Lu, G. Zlotnikov, A. D. Thor, and H. S. Smith, “Loss of heterozygosity in normal tissue adjacent to breast carcinomas,” Science, vol. 274, no. 5295, pp. 2057–2059, 1996.

[2] P. S. Larson, A. de las Morenas, L. A. Cupples, K. Huang, and C. L. Rosenberg, “Genetically abnormal clones in histologically normal breast tissue,” American Journal of Pathology, vol. 152, no. 6, pp. 1591–1598, 1998.

[3] S. R. Lakhani, R. Chaggar, S. Davies et al., “Genetic alterations in ‘normal’ luminal and myoepithelial cells of the breast,” Journal of Pathology, vol. 189, no. 4, pp. 496–503, 1999.

[4] L. R. Cavalli, B. Singh, C. Isaacs, R. B. Dickson, and B. R. Haddad, “Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer,” Cancer Genetics and Cytogenetics, vol. 149, no. 1, pp. 38–43, 2004.

[5] P. S. Larson, B. L. Schlechter, A. de las Morenas, J. E. Garber, L. A. Cupples, and C. L. Rosenberg, “Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8613–8619, 2005.

[6] P. S. Yan, C. Venkataramu, A. Ibrahim et al., “Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue,” Clinical Cancer Research, vol. 12, no. 22, pp. 6626–6636, 2006.

[7] C. M. Heaphy, M. Bisoffi, C. A. Fordyce et al., “Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors,” International Journal of Cancer, vol. 119, no. 1, pp. 108–116, 2006.

[8] A. Grigoriadis, A. Mackay, J. S. Reis-Filho et al., “Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data,” Breast Cancer Research, vol. 8, no. 5, article 56, 2006.

[9] G. Finak, S. Sadekova, F. Pepin et al., “Gene expression signatures of morphologically normal breast tissue identify basal-like tumors,” Breast Cancer Research, vol. 8, no. 5, article 58, 2006.

[10] A. Tripathi, C. King, A. De La Morenas et al., “Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients,” International Journal of Cancer, vol. 122, no. 7, pp. 1557–1566, 2008.

[11] D.-T. Chen, A. Nasir, A. Culhane et al., “Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue,” Breast Cancer Research and Treatment, vol. 119, no. 2, pp. 335–346, 2010.

[12] G. Arpino, R. Laucirica, and R. M. Elledge, “Premalignant and in situ breast disease: biology and clinical implications,” Annals of Internal Medicine, vol. 143, no. 6, pp. 446–457, 2005.

[13] S. Lee, S. K. Mohsin, S. Mao, D. Medina, and D. C. Allred, “Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer,” Breast Cancer Research, vol. 8, no. 1, article 6, 2006.

[14] M. A. Gonzalez, S. E. Finder, G. Callagy et al., “Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer,” Journal of Clinical Oncology, vol. 21, no. 23, pp. 4306–4313, 2003.

[15] T.-L. Mao, J. D. Seidman, R. J. Kurman, and L.-M. Shih, “Cyclin E and p16 immunoreactivity in epithelioid trophoblastic tumor — an aid in differential diagnosis,” American Journal of Surgical Pathology, vol. 30, no. 9, pp. 1105–1110, 2006.

[16] E. Burum-Auens, P. M. De Angelis, A. R. Schjolberg, K. L. Kravik, M. Aure, and O. P. F. Clausen, “Subcellular localization of the spindle proteins aura and Mad2, and BUBR1 assessed by immunohistochemistry,” Journal of Histochemistry and Cytochemistry, vol. 55, no. 5, pp. 477–486, 2007.

[17] Z. H. Meng, Y. Ben, Z. Li et al., “Aberrations of breast cancer susceptibility genes occur early in sporadic breast tumors and in acquisition of breast epithelial immortalization,” Genes Chromosomes and Cancer, vol. 41, no. 3, pp. 214–222, 2004.

[18] B. J. Lynch, D. G. Guiney Jr., and J. A. Holden, “Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer,” Human Pathology, vol. 26, no. 10, pp. 1180–1188, 1997.

[19] T.-K. Li and L. F. Liu, “Tumor cell death induced by topoisomerase-targeting drugs,” Annual Review of Pharmacology and Toxicology, vol. 41, pp. 53–77, 2001.
[20] B. G. Ju, V. V. Lunyak, V. Perissi et al., “A topoisoerase IIbeta-mediated dsDNA break required for regulated transcription,” *Science*, vol. 312, no. 5781, pp. 1798–1802, 2006.

[21] T. A. Jarvinen and E. T. Liu, “Simultaneous amplification of HER-2 (ERBB2) and topoisoerase IIalpha (TOP2A) genes—molecular basis for combination chemotherapy in cancer,” *Current Cancer Drug Targets*, vol. 6, no. 7, pp. 579–602, 2006.

[22] T. A. Jarvinen, M. Tanner, V. Rantaten et al., “Amplification and deletion of topoisoerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisoerase II inhibitor doxorubicin in breast cancer,” *American Journal of Pathology*, vol. 156, no. 3, pp. 839–847, 2000.

[23] S. Withoff, W. N. Keith, A. J. Knol et al., “Selection of a subpopulation with fewer DNA topoisoerase II alpha gene copies in a doxorubicin-resistant cell line panel,” *British Journal of Cancer*, vol. 74, no. 4, pp. 502–507, 1996.

[24] S. B. Wharton, K. K. Chan, J. R. Anderson, K. Stoeber, and H. Kato, T. Miyazaki, Y. Fukai et al., “A new proliferation licensing and human cell proliferation,” *Journal of Cell Science*, vol. 4, no. 4, pp. 213–217, 1988.

[25] B. G. Ju, V. V. Lunyak, V. Perissi et al., “A topoisomerase IIbeta-18 Pathology Research International

[26] T. A. Jarvinen, M. Tanner, V. Rantaten et al., “Amplification and deletion of topoisoerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisoerase II inhibitor doxorubicin in breast cancer,” *American Journal of Pathology*, vol. 156, no. 3, pp. 839–847, 2000.

[27] S. Withoff, W. N. Keith, A. J. Knol et al., “Selection of a subpopulation with fewer DNA topoisoerase II alpha gene copies in a doxorubicin-resistant cell line panel,” *British Journal of Cancer*, vol. 74, no. 4, pp. 502–507, 1996.

[28] S. B. Wharton, K. K. Chan, J. R. Anderson, K. Stoeber, and H. Kato, T. Miyazaki, Y. Fukai et al., “A new proliferation licensing and human cell proliferation,” *Journal of Cell Science*, vol. 4, no. 4, pp. 213–217, 1988.

[29] B. G. Ju, V. V. Lunyak, V. Perissi et al., “A topoisomerase IIbeta-18 Pathology Research International

[30] T. A. Jarvinen, M. Tanner, V. Rantaten et al., “Amplification and deletion of topoisoerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisoerase II inhibitor doxorubicin in breast cancer,” *American Journal of Pathology*, vol. 156, no. 3, pp. 839–847, 2000.

[31] S. Withoff, W. N. Keith, A. J. Knol et al., “Selection of a subpopulation with fewer DNA topoisoerase II alpha gene copies in a doxorubicin-resistant cell line panel,” *British Journal of Cancer*, vol. 74, no. 4, pp. 502–507, 1996.

[32] S. B. Wharton, K. K. Chan, J. R. Anderson, K. Stoeber, and H. Kato, T. Miyazaki, Y. Fukai et al., “A new proliferation licensing and human cell proliferation,” *Journal of Cell Science*, vol. 4, no. 4, pp. 213–217, 1988.

[33] B. G. Ju, V. V. Lunyak, V. Perissi et al., “A topoisomerase IIbeta-18 Pathology Research International

[34] T. A. Jarvinen, M. Tanner, V. Rantaten et al., “Amplification and deletion of topoisoerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisoerase II inhibitor doxorubicin in breast cancer,” *American Journal of Pathology*, vol. 156, no. 3, pp. 839–847, 2000.

[35] S. Withoff, W. N. Keith, A. J. Knol et al., “Selection of a subpopulation with fewer DNA topoisoerase II alpha gene copies in a doxorubicin-resistant cell line panel,” *British Journal of Cancer*, vol. 74, no. 4, pp. 502–507, 1996.

[36] S. B. Wharton, K. K. Chan, J. R. Anderson, K. Stoeber, and H. Kato, T. Miyazaki, Y. Fukai et al., “A new proliferation licensing and human cell proliferation,” *Journal of Cell Science*, vol. 4, no. 4, pp. 213–217, 1988.